| Outcome Measures: |
Primary: Hba1c change from baseline to 6 months post randomization, At baseline and at 6 months after randomization | Secondary: Evolution of Hba1c from baseline to 2 years post-randomization, At baseline and at 6 weeks, 12 weeks, 18 weeks, 24 weeks, 1 year and 2 years post randomization|Evolution of C-peptide from baseline to 2 years post-randomization, At baseline and at 6 weeks, 12 weeks, 18 weeks, 24 weeks, 1 year and 2 years post randomization|Evolution of insulin secretion from baseline to 24 weeks using the HOMA-B calculator, Equal to 20 x fasting insulin (μIU/ml)/ fasting glucose (mmol/ml) - 3.5, At baseline and at 24 weeks post-randomization|Evolution of insulin resistance from baseline to 24 weeks, we will use the HOMA-IR (= fasting insulin (μIU/ml) × fasting glucose (mmol/ml)/ 22.5) and Disse index (=Disse 12\*((2.5\*(HDL-total cholesterol)-NEFA)-insulin)) which are two complementary markers to evaluate insulin resistance using different parameters, At baseline and at 24 weeks post-randomization|Glycaemia profile (using glycemic holter) changes from baseline to 6 weeks and 24 weeks, Glycemic holter will be placed on the patient for 3 days at baseline, 6 weeks and 6 months and will collect glycemic curve excursions that will further be compared at the different visits (baseline, 6 and 24 weeks). We will analyse the % and duration of hyperglycemia and hypoglycaemia and the % of time and duration at glycemic target at the different visits (baseline, 6 and 24 weeks), At baseline and at 6 weeks and 24 weeks post-randomization|Number of anti-diabetic (antiT2D) drugs, The number of concomitant anti-diabetic drugs will be analysed, At baseline and at 1 and 2 years post-randomization|Type of antiT2D drugs, The type of anti-diabetic drugs will be analysed, At baseline and at 1 and 2 years post-randomization|Number of patients reaching Diabetic Remission (DR), At baseline and at 24 weeks, 1 and 2 years post-randomization|Proportion of patient needing a "safety" glucose lowering treatment to control Hba1c despite FMTs (or placebo), From baseline to 2 years post-randomization|Evaluate FMT safety, Evaluate safety and AE by a systematic screening regarding fever, bloating, diarrhoea, regurgitation at each visit, From baseline to 2 years post-randomization|Evaluate quality of life, Evaluate changes in quality of life after capsulized FMT (baseline vs. after FMT and between treatment groups using SF36 questionnaire), At baseline and at 6 weeks, 12 weeks, 18 weeks, 24 weeks, 1 year and 2 years post randomization
|
